Annual CFI
-$4.06 B
-$1.10 B-37.30%
31 December 2023
Summary:
AstraZeneca annual cash flow from investing activities is currently -$4.06 billion, with the most recent change of -$1.10 billion (-37.30%) on 31 December 2023. During the last 3 years, it has fallen by -$3.78 billion (-1325.96%). AZN annual CFI is now -518.97% below its all-time high of $970.00 million, reached on 31 December 2004.AZN Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$1.51 B
+$1.36 B+47.28%
30 September 2024
Summary:
AstraZeneca quarterly cash flow from investing activities is currently -$1.51 billion, with the most recent change of +$1.36 billion (+47.28%) on 30 September 2024. Over the past year, it has dropped by -$293.00 million (-24.00%). AZN quarterly CFI is now -180.02% below its all-time high of $1.89 billion, reached on 30 June 2006.AZN Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$7.88 B
-$293.00 M-3.86%
30 September 2024
Summary:
AstraZeneca TTM cash flow from investing activities is currently -$7.88 billion, with the most recent change of -$293.00 million (-3.86%) on 30 September 2024. Over the past year, it has dropped by -$4.64 billion (-143.39%). AZN TTM CFI is now -616.46% below its all-time high of $1.52 billion, reached on 30 June 2005.AZN TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -37.3% | -24.0% | -143.4% |
| 3 y3 years | -1326.0% | +85.5% | +21.3% |
| 5 y5 years | -522.0% | -2145.9% | -3815.1% |
AZN Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1326.0% | +63.3% | -801.2% | +85.5% | -166.1% | +36.2% |
| 5 y | 5 years | -522.0% | +63.3% | -372.8% | +85.5% | -2825.3% | +36.2% |
| alltime | all time | -519.0% | +72.7% | -180.0% | +89.1% | -616.5% | +54.2% |
AstraZeneca Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.51 B(-47.3%) | -$7.88 B(+3.9%) |
| June 2024 | - | -$2.87 B(+19.0%) | -$7.58 B(+45.0%) |
| Mar 2024 | - | -$2.41 B(+124.0%) | -$5.23 B(+28.7%) |
| Dec 2023 | -$4.06 B(+37.3%) | -$1.08 B(-11.8%) | -$4.06 B(+25.6%) |
| Sept 2023 | - | -$1.22 B(+134.8%) | -$3.24 B(-13.9%) |
| June 2023 | - | -$520.00 M(-58.3%) | -$3.76 B(-6.9%) |
| Mar 2023 | - | -$1.25 B(+400.4%) | -$4.04 B(+36.4%) |
| Dec 2022 | -$2.96 B(-73.2%) | -$249.00 M(-85.7%) | -$2.96 B(-18.3%) |
| Sept 2022 | - | -$1.74 B(+117.9%) | -$3.62 B(-70.6%) |
| June 2022 | - | -$800.00 M(+376.2%) | -$12.35 B(+4.8%) |
| Mar 2022 | - | -$168.00 M(-81.6%) | -$11.78 B(+6.5%) |
| Dec 2021 | -$11.06 B(+3780.0%) | -$913.00 M(-91.3%) | -$11.06 B(+10.5%) |
| Sept 2021 | - | -$10.46 B(+4333.9%) | -$10.01 B(+8035.8%) |
| June 2021 | - | -$236.00 M(-142.5%) | -$123.00 M(-147.1%) |
| Mar 2021 | - | $555.00 M(+302.2%) | $261.00 M(-191.6%) |
| Dec 2020 | -$285.00 M(-56.6%) | $138.00 M(-123.8%) | -$285.00 M(-21.9%) |
| Sept 2020 | - | -$580.00 M(-491.9%) | -$365.00 M(-226.3%) |
| June 2020 | - | $148.00 M(+1544.4%) | $289.00 M(-129.6%) |
| Mar 2020 | - | $9.00 M(-84.5%) | -$976.00 M(+48.6%) |
| Dec 2019 | -$657.00 M(-168.2%) | $58.00 M(-21.6%) | -$657.00 M(-409.9%) |
| Sept 2019 | - | $74.00 M(-106.6%) | $212.00 M(-7166.7%) |
| June 2019 | - | -$1.12 B(-440.5%) | -$3.00 M(-100.3%) |
| Mar 2019 | - | $328.00 M(-64.6%) | $1.02 B(+5.7%) |
| Dec 2018 | $963.00 M(-141.4%) | $927.00 M(-757.4%) | $963.00 M(-160.0%) |
| Sept 2018 | - | -$141.00 M(+46.9%) | -$1.61 B(-10.8%) |
| June 2018 | - | -$96.00 M(-135.2%) | -$1.80 B(-5.7%) |
| Mar 2018 | - | $273.00 M(-116.6%) | -$1.91 B(-18.0%) |
| Dec 2017 | -$2.33 B(-41.3%) | -$1.64 B(+390.1%) | -$2.33 B(+2704.8%) |
| Sept 2017 | - | -$335.00 M(+63.4%) | -$83.00 M(-77.7%) |
| June 2017 | - | -$205.00 M(+40.4%) | -$372.00 M(-69.7%) |
| Mar 2017 | - | -$146.00 M(-124.2%) | -$1.23 B(-69.1%) |
| Dec 2016 | -$3.97 B(-6.4%) | $603.00 M(-196.6%) | -$3.97 B(-44.5%) |
| Sept 2016 | - | -$624.00 M(-41.2%) | -$7.16 B(+2.9%) |
| June 2016 | - | -$1.06 B(-63.2%) | -$6.95 B(+5.8%) |
| Mar 2016 | - | -$2.89 B(+11.7%) | -$6.57 B(+55.0%) |
| Dec 2015 | -$4.24 B(-39.7%) | -$2.58 B(+515.5%) | -$4.24 B(+33.7%) |
| Sept 2015 | - | -$420.00 M(-38.1%) | -$3.17 B(-4.3%) |
| June 2015 | - | -$678.00 M(+21.9%) | -$3.31 B(-13.1%) |
| Mar 2015 | - | -$556.00 M(-63.3%) | -$3.81 B(-45.8%) |
| Dec 2014 | -$7.03 B(+143.4%) | -$1.52 B(+170.2%) | -$7.03 B(+7.9%) |
| Sept 2014 | - | -$561.00 M(-52.4%) | -$6.52 B(-1.3%) |
| June 2014 | - | -$1.18 B(-68.8%) | -$6.61 B(+4.8%) |
| Mar 2014 | - | -$3.78 B(+276.2%) | -$6.30 B(+118.1%) |
| Dec 2013 | -$2.89 B(+55.4%) | -$1.00 B(+55.2%) | -$2.89 B(+20.4%) |
| Sept 2013 | - | -$647.00 M(-26.0%) | -$2.40 B(-46.1%) |
| June 2013 | - | -$874.00 M(+140.1%) | -$4.45 B(+58.0%) |
| Mar 2013 | - | -$364.00 M(-29.2%) | -$2.82 B(+51.5%) |
| Dec 2012 | -$1.86 B(-8.1%) | -$514.00 M(-80.9%) | -$1.86 B(-62.3%) |
| Sept 2012 | - | -$2.70 B(-455.0%) | -$4.92 B(+415.7%) |
| June 2012 | - | $760.00 M(+28.2%) | -$955.00 M(-37.5%) |
| Mar 2012 | - | $593.00 M(-116.6%) | -$1.53 B(-24.4%) |
| Dec 2011 | -$2.02 B | -$3.58 B(-381.4%) | -$2.02 B(-282.8%) |
| Sept 2011 | - | $1.27 B(+583.9%) | $1.11 B(+1102.2%) |
| June 2011 | - | $186.00 M(+86.0%) | $92.00 M(-109.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2011 | - | $100.00 M(-122.1%) | -$1.02 B(-54.2%) |
| Dec 2010 | -$2.23 B(-10.1%) | -$452.00 M(-275.2%) | -$2.23 B(-39.5%) |
| Sept 2010 | - | $258.00 M(-127.9%) | -$3.68 B(-15.4%) |
| June 2010 | - | -$925.00 M(-16.4%) | -$4.35 B(+18.8%) |
| Mar 2010 | - | -$1.11 B(-41.9%) | -$3.66 B(+47.7%) |
| Dec 2009 | -$2.48 B(-36.4%) | -$1.90 B(+364.4%) | -$2.48 B(+129.0%) |
| Sept 2009 | - | -$410.00 M(+73.7%) | -$1.08 B(+25.8%) |
| June 2009 | - | -$236.00 M(-418.9%) | -$859.00 M(-4.4%) |
| Mar 2009 | - | $74.00 M(-114.5%) | -$899.00 M(-76.9%) |
| Dec 2008 | -$3.90 B(-73.8%) | -$509.00 M(+170.7%) | -$3.90 B(+1.9%) |
| Sept 2008 | - | -$188.00 M(-31.9%) | -$3.82 B(+6.4%) |
| June 2008 | - | -$276.00 M(-90.6%) | -$3.59 B(-79.1%) |
| Mar 2008 | - | -$2.92 B(+570.4%) | -$17.20 B(+15.5%) |
| Dec 2007 | -$14.89 B(+5373.2%) | -$436.00 M(-1138.1%) | -$14.89 B(+5.1%) |
| Sept 2007 | - | $42.00 M(-100.3%) | -$14.17 B(-4.0%) |
| June 2007 | - | -$13.88 B(+2156.6%) | -$14.75 B(-1552.2%) |
| Mar 2007 | - | -$615.00 M(-318.9%) | $1.02 B(-473.5%) |
| Dec 2006 | -$272.00 M(-77.0%) | $281.00 M(-151.8%) | -$272.00 M(-75.7%) |
| Sept 2006 | - | -$542.00 M(-128.6%) | -$1.12 B(-33.0%) |
| June 2006 | - | $1.89 B(-199.4%) | -$1.67 B(-45.4%) |
| Mar 2006 | - | -$1.90 B(+236.2%) | -$3.06 B(+158.9%) |
| Dec 2005 | -$1.18 B(-221.9%) | -$566.00 M(-48.2%) | -$1.18 B(-212.8%) |
| Sept 2005 | - | -$1.09 B(-317.7%) | $1.05 B(-31.3%) |
| June 2005 | - | $502.00 M(-2108.0%) | $1.52 B(+1.1%) |
| Mar 2005 | - | -$25.00 M(-101.5%) | $1.51 B(+55.6%) |
| Dec 2004 | $970.00 M(-213.8%) | $1.66 B(-370.1%) | $970.00 M(-278.3%) |
| Sept 2004 | - | -$616.00 M(-226.7%) | -$544.00 M(-26.8%) |
| June 2004 | - | $486.00 M(-186.2%) | -$743.48 M(-31.5%) |
| Mar 2004 | - | -$564.00 M(-476.0%) | -$1.09 B(+27.4%) |
| Dec 2003 | -$852.00 M(-44.8%) | $150.00 M(-118.4%) | -$852.00 M(-43.7%) |
| Sept 2003 | - | -$815.48 M(-666.2%) | -$1.51 B(+38.0%) |
| June 2003 | - | $144.03 M(-143.6%) | -$1.10 B(-31.0%) |
| Mar 2003 | - | -$330.54 M(-35.3%) | -$1.59 B(+3.0%) |
| Dec 2002 | -$1.54 B(-2.8%) | -$511.27 M(+28.2%) | -$1.54 B(-2.6%) |
| Sept 2002 | - | -$398.73 M(+14.6%) | -$1.58 B(+2.8%) |
| June 2002 | - | -$348.00 M(+22.1%) | -$1.54 B(+0.9%) |
| Mar 2002 | - | -$285.00 M(-48.5%) | -$1.53 B(-3.7%) |
| Dec 2001 | -$1.59 B(+22.7%) | -$553.00 M(+55.3%) | -$1.59 B(+19.5%) |
| Sept 2001 | - | -$356.00 M(+6.5%) | -$1.33 B(-33.6%) |
| June 2001 | - | -$334.12 M(-2.8%) | -$2.00 B(+48.9%) |
| Mar 2001 | - | -$343.88 M(+16.9%) | -$1.34 B(+3.8%) |
| Dec 2000 | -$1.29 B(+71.8%) | -$294.29 M(-71.3%) | -$1.29 B(+29.5%) |
| Sept 2000 | - | -$1.03 B(-418.4%) | -$999.17 M(-3668.0%) |
| June 2000 | - | $322.62 M(-209.5%) | $28.00 M(-109.5%) |
| Mar 2000 | - | -$294.62 M | -$294.62 M |
| Dec 1999 | -$753.00 M(-77.7%) | - | - |
| Dec 1998 | -$3.38 B(+489.6%) | - | - |
| Dec 1997 | -$573.63 M(+4.7%) | - | - |
| Dec 1996 | -$548.00 M(-15.6%) | - | - |
| Dec 1995 | -$648.99 M(+44.1%) | - | - |
| Dec 1994 | -$450.26 M(+15.7%) | - | - |
| Dec 1993 | -$389.03 M(+45.7%) | - | - |
| Dec 1992 | -$266.94 M(+30.9%) | - | - |
| Dec 1991 | -$203.96 M(+211.0%) | - | - |
| Dec 1990 | -$65.58 M | - | - |
FAQ
- What is AstraZeneca annual cash flow from investing activities?
- What is the all time high annual CFI for AstraZeneca?
- What is AstraZeneca annual CFI year-on-year change?
- What is AstraZeneca quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for AstraZeneca?
- What is AstraZeneca quarterly CFI year-on-year change?
- What is AstraZeneca TTM cash flow from investing activities?
- What is the all time high TTM CFI for AstraZeneca?
- What is AstraZeneca TTM CFI year-on-year change?
What is AstraZeneca annual cash flow from investing activities?
The current annual CFI of AZN is -$4.06 B
What is the all time high annual CFI for AstraZeneca?
AstraZeneca all-time high annual cash flow from investing activities is $970.00 M
What is AstraZeneca annual CFI year-on-year change?
Over the past year, AZN annual cash flow from investing activities has changed by -$1.10 B (-37.30%)
What is AstraZeneca quarterly cash flow from investing activities?
The current quarterly CFI of AZN is -$1.51 B
What is the all time high quarterly CFI for AstraZeneca?
AstraZeneca all-time high quarterly cash flow from investing activities is $1.89 B
What is AstraZeneca quarterly CFI year-on-year change?
Over the past year, AZN quarterly cash flow from investing activities has changed by -$293.00 M (-24.00%)
What is AstraZeneca TTM cash flow from investing activities?
The current TTM CFI of AZN is -$7.88 B
What is the all time high TTM CFI for AstraZeneca?
AstraZeneca all-time high TTM cash flow from investing activities is $1.52 B
What is AstraZeneca TTM CFI year-on-year change?
Over the past year, AZN TTM cash flow from investing activities has changed by -$4.64 B (-143.39%)